Aastrom Announces Appointment of Zac Taylor as National Sales Director
July 14 2014 - 7:30AM
Aastrom Biosciences, Inc. (Nasdaq:ASTM), the leading developer of
patient-specific expanded cellular therapies for the treatment of
severe diseases and conditions, today announced the appointment of
Zac Taylor as national sales director.
"We are thrilled to have Zac join Aastrom as our national sales
director. He has an impressive track record in both new product
launches as well as reinvigorating established brands," said Daniel
Orlando, chief operating officer of Aastrom. "Zac's proven skill
set will be of great value to Aastrom as we continue to develop our
talented team and work to realize the commercial potential of
Carticel and Epicel and prepare for the eventual launch of MACI in
the U.S."
Mr. Taylor has over 22 years of experience in pharmaceutical and
medical device sales and marketing, leading numerous commercial
organizations with a consistent record of increasing revenue,
market share and profitability in both start-ups and established
corporate environments. Mr. Taylor previously served as national
sales director for Abbott, where his leadership of the U.S.
commercial sales organization significantly improved growth and
profitability. As a regional business director at Pfizer, he
consistently met sales goals across several teams, and earned many
distinctions and awards for his work. Mr. Taylor also helped build
and lead the commercial organization at Takeda Pharmaceuticals
North America in a variety of sales and marketing leadership roles.
Mr. Taylor earned an MBA from St. Joseph's University and a
bachelor of arts in business communications from the University of
Oklahoma.
"I am excited to join an organization which is marketing and
developing pioneering cell based therapies. I am confident there is
significant growth potential remaining in both Carticel and Epicel,
and I look forward to working with the regarded Aastrom sales and
marketing organization to expand the usage of these products, each
of which offers unique benefits to patients not available from
other therapies," said Mr. Taylor. About Aastrom
Biosciences
Aastrom Biosciences is the leader in developing patient-specific
expanded cellular therapies for use in the treatment of patients
with severe diseases and conditions. Aastrom markets two autologous
cell therapy products in the United States for the treatment of
cartilage repair and skin replacement. Aastrom is also developing
MACI, a third generation autologous chondrocyte implant for the
treatment of cartilage defects in the knee, and ixmyelocel-T, a
patient-specific multicellular therapy for the treatment of
advanced heart failure due to ischemic dilated cardiomyopathy. For
more information, please visit Aastrom's website at
www.aastrom.com.
The Aastrom Biosciences, Inc. logo is available
at http://www.globenewswire.com/newsroom/prs/?pkgid=3663 This
document contains forward-looking statements, including, without
limitation, statements concerning anticipated progress, objectives
and expectations regarding the commercial potential of our products
and growth in revenues, and objectives and expectations regarding
the business opportunity described herein, all of which involve
certain risks and uncertainties. These statements are often, but
are not always, made through the use of words or phrases such as
"anticipates," "intends," "estimates," "plans," "expects," "we
believe," "we intend," and similar words or phrases, or future or
conditional verbs such as "will," "would," "should," "potential,"
"could," "may," or similar expressions. Actual results may differ
significantly from the expectations contained in the
forward-looking statements. Among the factors that may result in
differences are the inherent risks and uncertainties associated
with competitive developments, product development activities, the
availability and allocation of resources among different potential
uses, estimating the commercial potential of our products and
growth in revenues, market demand for our products, and our ability
to supply or meet customer demand for our products. These and
other significant factors are discussed in greater detail in
Aastrom's Annual Report on Form 10-K for the year ended December
31, 2013, filed with the Securities and Exchange Commission ("SEC")
on March 13, 2014, Quarterly Reports on Form 10-Q and other filings
with the SEC. These forward-looking statements reflect management's
current views and Aastrom does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release
except as required by law.
CONTACT: Media contact:
David Salisbury
Berry & Company
dsalisbury@berrypr.com
(212) 253-8881
Investor contact:
Chad Rubin
The Trout Group
crubin@troutgroup.com
(646) 378-2947
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Sep 2024 to Oct 2024
Vericel (NASDAQ:VCEL)
Historical Stock Chart
From Oct 2023 to Oct 2024